Skip to main navigation
Manage consent
Kronos Bio logoKronos Bio logo

Investor Relations

  • Company
    • About Us
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Our Stories
    • Policies & Notices
    • Contact Page
  • Science & Pipeline
    • Discovery
    • Pipeline
    • Publications
  • Clinical Trials
  • Investors & Media
    • Overview
    • Press Releases
    • Events & Presentations
    • Stock Information
      • Stock Quote & Chart
      • Analyst Coverage
    • Corporate Governance
    • SEC Filings
    • Financials & Filings
      • Quarterly Results
    • IR Resources
      • Investor FAQs
      • Email Alerts
      • Investor & Media Contact
  • Careers
Menu

Investor Relations - Top Nav

  • Company
    • About Us
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Our Stories
    • Policies & Notices
    • Contact Page
  • Science & Pipeline
    • Discovery
    • Pipeline
    • Publications
  • Clinical Trials
  • Investors & Media
    • Overview
    • Press Releases
    • Events & Presentations
    • Stock Information
      • Stock Quote & Chart
      • Analyst Coverage
    • Corporate Governance
    • SEC Filings
    • Financials & Filings
      • Quarterly Results
    • IR Resources
      • Investor FAQs
      • Email Alerts
      • Investor & Media Contact
  • Careers

Press Releases

Aug 04, 2022
Kronos Bio Reports Recent Business Progress and Second-Quarter 2022 Financial Results
Jun 10, 2022
Kronos Bio Continues to Advance Investigational SYK Inhibitors Entospletinib and Lanraplenib with New Preclinical Data at EHA2022 Congress
Jun 01, 2022
Kronos Bio Announces Participation in Upcoming Investor Conferences
May 17, 2022
Kronos Bio Announces Participation in H.C. Wainwright Global Investment Conference
May 12, 2022
Kronos Bio’s Investigational SYK Inhibitors Entospletinib and Lanraplenib to be Featured in Four Poster Presentations at EHA2022 Congress
May 04, 2022
Kronos Bio Reports Recent Business Progress and First-Quarter 2022 Financial Results
Apr 08, 2022
Kronos Bio Presents Preclinical Data on Oral CDK9 Inhibitor KB-0742, Providing Additional Evidence of Potential Efficacy in MYC-Amplified and Transcriptionally Addicted Tumors at AACR
Mar 08, 2022
Kronos Bio’s Investigational CDK9 Inhibitor KB-0742 to be Featured in Four Preclinical Poster Presentations at American Association for Cancer Research Annual Meeting 2022
Mar 01, 2022
Kronos Bio Announces Participation in Cowen 42nd Annual Health Care Conference
Feb 24, 2022
Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2021 Financial Results
Feb 01, 2022
Kronos Bio Announces Appointment of Elizabeth Olek as Senior Vice President of Clinical Development

Contact

Headquarters

Kronos Bio, Inc.
1300 So. El Camino Real
Suite 400
San Mateo, CA 94402
+1 (650) 781-5200

Research Facility

Kronos Bio, Inc.
301 Binney Street
2nd Floor East
Cambridge, MA 02142

PARTNERING INQUIRIES

bd@kronosbio.com

MEDIA INQUIRIES

media@kronosbio.com

INVESTOR INQUIRIES

investor@kronosbio.com

EMPLOYMENT INQUIRIES

careers@kronosbio.com

 

  • Linkedin
UK and EU Privacy Contacts
Policies & Notices

© 2022 All rights reserved.

TOP